Chemo Catalogue 2012

7/28/2019 Chemo Catalogue 2012

1/206

PATCH TESTPRODUCTS2012

World Leader in Patch Testing


2/206


3/206

A3

...for the diagnosis of contact allergy

CATALOGUE

January 2012

The completerange of products for

Patch Testing

ChemotechniqueDiagnostics


4/206

A4

Chemotechnique Diagnostics

Preface by Bo Niklasson, Founder and CEO

of Chemotechnique Diagnostics

In our 30 years of successful operation, since 1981, our continuingcorporate objective at Chemotechnique Diagnostics has been to berecognized as the most competent and innovative organization fo-cused on meeting the needs of dermatology physicians specializing incontact dermatitis and patch testing. Implicit in this objective is our

commitment to undertake and promote marketing leading researchand innovation, while being accountable for the highest quality ma-nufacturing, promotion, and distribution. This continuing focus hasresulted in the development of the widest range of patch test haptenscombined with the most advanced and innovative test chamber unitsand accessories. This has resulted in Chemotechnique Diagnostics be-ing the only company producing the full range of products needed by

physicians world-wide for performing patch testing.

Chemotechnique Diagnostics 30 years of continuous growth and de-velopment has been the result of our belief in building strong andlong term business relationships with our global network of distribu-tors, combined with the ongoing support and contributions of ourproduct-user base of physicians. As a result, Chemotechnique Diag-nostics is recognized as the world leading patch test producing com-pany. Our commitment is to continue serving dermatology in futureyears... maintaining our leadership position.

Over our 30 years of operation we have consistently supported phy-sicians specializing in contact dermatitis in developing country and

regional research groups and associations interested in advancing thepractice of patch testing. Additionally, Chemotechnique supports theworkshops of dermatology associations designed to enhance the patchtesting knowledge and skills of dermatologists.

As a result of this interaction, and the research capabilities of Che-motechnique, we have been honoured to participate in breakthrough

cooperative research activities. These international studies have con-


5/206

A5


tributed to the significant advances made in the field of contact der-matitis. The following are two current examples of the benefits of this

research cooperation.

Over the past two years, in cooperation with Gothenburg University,department of Chemistry, two important Fragrance haptens have beendeveloped. These two haptens, found in many perfumed products, areHydroperoxides of Linalool, 1% pet (H-031) and Hydroperoxides ofLimonene, 0.3% pet (H-032). These haptens were included in a multi-center study producing a much higher yield of allergic reactions thanthe previously used corresponding haptens and they will be availablein the Chemotechnique range from January 2012.The other field of research has involved a multicenter study of photo-haptens to determine what haptens produce the highest frequency of

photoallergic reactions.During the year we have also continued to expand our distributionnetwork to include several new countries.

We now look forward to 2012, identifying and maximizing marketand product development opportunities, all focused on the global ad-

vancement of patch testing.

Finally, I invite your participation in our important mission:Our mission is to provide an improved quality of life for the vastnumber of people worldwide suffering from conditions caused by

contact allergy.

Bo Niklasson,

Founder and CEO


6/206


A6

DISTRIBUTOR

Production: Chemotechnique Diagnostics

Printing: JMS Mediasystem 2012 Revised: January 2012

Copyright : Chemotechnique Diagnostics AB

Patch Test Productsauthorized by the ICDRG

Distributed Worldwide


7/206

1


CATALOGUE 2012Content Page

PREFACE BY BO NIKLASSON, CEO ...............................................A2-A3

THE CHEMOTECHNIQUE STORY ...................................................2-13

CHEMOTECHNIQUE DIAGNOSTICS WEBSITE ................................14

OUR PRODUCTS .................................................................................16-17

IQ ULTRA INFORMATION ..............................................................18-19

PATCH TEST TECHNIQUE IQ ULTRA..........................................20-22

IQ ULTIMATE INFORMATION ........................................................... 23

IQ CHAMBER INFORMATION .........................................................24-25

PATCH TEST TECHNIQUE IQ CHAMBER .....................................26-27

GENERAL INFORMATION/REFERENCES FOR CHAMBERS .....29-31

PATCH TEST PRODUCTS ..................................................................32-33

PRESENTATION OF SELECTED HAPTEN SERIES .......................34-67

PATCH TEST RECORD FORM ...............................................................67

TABLE OF MIXES ................................................................................68-73

CHEMICAL ABBREVIATIONS ..............................................................74

LIST OF SYNONYMS ...............................................................................74

TRADE NAMES OF PRODUCTS ...........................................................74

PATIENT INFORMATION SHEET ..........................................................74

ARTICLE GUIDE TO HAPTENS ........................................................75-88

ABBRS IN THE TABLE OF HAPTENS ................................................. 89

TABLE OF HAPTENS ........................................................................90-186

CATALOGUE AMENDMENTS ......................................................187-195

ORDERING PROCEDURE ...................................................................196

CONDITIONS OF SALE .................................................................196-197

Table of Contents


8/206

2


The Chemotechnique Story*

PreambleChemotechnique Diagnostics was founded in 1981 by Bo Niklasson, at thattime active in the clinical and scientific work at the Department of Occupa-tional Dermatology in Malm University Hospital, Sweden. This chapter is anattempt to summarize my work of 30 years in developing the company froma small side activity to a world leading company in the field of patch testingproducts currently providing products to around 90 countries.

Dedication and acknowledgments by Bo Niklasson, founder and

president of Chemotechnique DiagnosticsI want to dedicate this chapter to mydear wife Marie with a lot of love, shehas given me faithful support and encou-ragement since the start of the company,a great inspiration for me and a discus-sion partner in strategic planning onmany occasions. Without her supportthe company would not exist today.To my bright daughter Helena for va-luable legal advise related to intellectualproperty, to my artistic and inventiveson David for brilliant ideas within in-

dustrial design, to my son in law Fredrikfor skillful help with economy and webdesign, to my father Gte and motherLill who provided money for the firstbalance in the lab, to Gte who gave va-luable practical help in the first period

of the business after his retirement, to my wonderful staff for skillful and hard

work, to Sven-Inge Svensson KPMG for professional accounting and advise,to Dan Lindmark at Lindmark Welinder law firm for precious overall legaladvise, to Jan Sturesson at Price Waterhouse Coopers for valuable advise incompany organization and strategic planning, to Magnus Hilleskog for skill-fully managing the land and premises, to Tommy Lindn for great artwork incatalogs and marketing material and to Magnus Hansson for incredible designand construction of equipment and machines, all of you have been of greathelp over the past decades.

In the chapter I mention persons that have been important and related to


9/206

3


the business in many different ways, I will most likely forget some as my me-mory not always serves me and therefore I take the opportunity to apologize

for this already in the beginning of the chapter.

The clinical work and the start of the CompanyThe birth of Chemotechnique Diagnostics took place in 1981 in Malm,Sweden. At that time I had a few years before, in 1978, by Professor BertilMagnusson and Professor Bert Bjrkner been offered the opportunity to bepart of the new Department of Occupational Dermatology at the UniversityHospital in Malm as responsible chemist for the patch testing laboratory.I am grateful for all knowledge and guidance that was given to me during my

work at the clinic from Professor Sigfrid Fregert, Professor Bertil Magnusson,Professor Halvor Mller and Professor Bert Bjrkner later followed by Profes-sor Magnus Bruze. I was involved in many research projects including Bertsthesis work covering occupational contact allergy to acrylates where I did mostof the analytical work and a lot of the Guinea Pig Maximization work original-ly developed by Magnusson and Kligman. My background within Chemistry

and Biomedicine, later followed by Dermatology courses as well as my expe-rience from the clinical work, gave me insight and means to develop a numberof different test series related to various occupations and exposures to a wide

variety of haptens. These substances were found in products handled at thework place in many different industrial environments. Numerous contactswith companies producing such products providing information on ingredi-ents facilitated the selection of substances to be investigated. An important

aspect of patch testing is the knowledge how to prepare the patients ownproducts brought in from the work place. I was offered the opportunity toshare my experience in this field by professor Jere Guin in his book PracticalContact Dermatitis from 1995 (Mc Graw Hill) as well as providing hapten in-formation in Handbook of Occupational Dermatology by Kanerva, Wahlbergand Maibach in the year 2000. One important compound that we discoveredmany contact allergies to was the preservative with the brand name KathonCG manufactured by Rohm and Haas company in USA. This became a quite

sensitive issue and the chief toxicologist from the company visited us to dis-cuss the matter. Other interesting compounds causing outbreaks of allergiccontact dermatitis were various acrylates in the printing industry.The actual reason for starting the company was related to a Swedish multicen-ter clinical trial of a new test series of haptens for diagnosing contact allergyin dental staff and patients undergoing dental treatments. The name of theseries for the selected haptens was "Dental Screening series". The clinics had

to get the material for testing and as such the possibility and proper time to


10/206


4

prepare the material at the clinic was simply not available. The result afterdiscussing the project with the hospital legal department was to provide the

material through a company instead of the clinic. So, I took on the task, star-ted the company in 1981, at that time named Kemoteknik, and assisted in theinitial period by my coworker Bjrn Edman at the Dermatology department.The research work investigating the dental screening series was finalized andresulted in a publication in Contact Dermatitis.

The development of the companyMy wife Marie was directly involved in the work and remained so for many

years with important contributions to the development of the company. Theactivities in the company were divided after a short period in such a way thatthe continued development and sales of a computer software named Daluk,for the management of patch testing data, which was Bjrns baby was takenover by him and he started a company of his own to manage this. I could thenfully focus on the development of new test series of haptens as there was in

my experience a great lack of com-

mercially available substances inthe beginning of the 80s. What ex-isted was the limited Trolab rangemade by the Danish pharmacistsTrolle Lassen in Copenhagen. Inthis period of time I learned howto become an entrepreneur andstarted to build an internationalmarket organization through distri-

butors. It was hard work as I, like many other small entrepreneurs, started inthe basement of my house and as this was a side activity to my normal work atthe clinic, the working hours were long and arduous.The company changed its name to Chemotechnique Diagnostics in 1984 andour neighbors daughter Elisabet Magnusson freshly graduated as a chemist

was employed and she has remained a faithful coworker throughout this long

period of time. Continued research and development of selected test seriestook place and the range expanded year by year. Also, the distribution networkcontinued to expand and worth mentioning is the first distributor Bill van derBend, in the Netherlands followed by Eddy Luyckx (Dermat), in Belgium. Icontinued working at the Department of Occupational and EnvironmentalDermatology until 1995 when time just wasnt enough to allow me to keepon at the same time running and developing the company. I was grateful for

the 17 years I spent at the clinic and thankful for all valuable time that I spent


11/206

...the trusted name in patch testing

5

with colleagues, involved in the patient investigations and research work thatresulted in many publications over the years. As the company grew the produc-

tion facilities grew as well and several moves to new buildings and locationstook place within the Malm area.The most recent move was made in2005 and when looking back I findthat the adventure started in a 30m2basement and now the operationstake place in a 1600 m2 industrialbuilding in Vellinge just south ofMalm. The latest move involved alot of work as a completely new stateof the art laboratory had to be built

at the same time as trying to keep deliveries and production going withouttoo much interruption. All details fulfilling the requirements of a pharmaceu-tical laboratory working under GMP/GLP conditions needed to be put in

place when designing the lab. Whenthe move was finalized it was a greatpleasure to start working in a modernbuilding with large storage facilitiesas well. Also, the continuous growthof number of staff in the laboratory,medical device department and order

and customer service has been a plea-sure to follow and I greatly value the hard work and contributions to thedevelopment of the business that my coworkers provide. During many yearsa lot of money, energy and time have been invested in developing methodsand setting up new equipment in the laboratory for production and analysissuch as HPLC, GC, FT-IR (Chromatography and Spectroscopy) etc. Worthmentioning is the intricate machine that fills and labels the syringes which

was built from scratch through a valuable cooperation with the construction

engineer Magnus Hansson who has been involved in building several othermachines including test chamber production machines. The continuous workin research and development of new test substances has resulted in the wi-dest range of commercially available haptens, now covering around 550 testpreparations, and new material will be added continually depending on theneeds from the dermatology field. Parallel to this development has been thedevelopment of the company website with the primary focus to provide an

extensive multilingual database of knowledge about the haptens as a service


12/206


13/206

...world leader in patch testing

7

Distribution network, marketing and cooperation with Contact

Dermatitis Research Groups

I have enjoyed a thrilling voyage over the years in building a worldwide net-work of distributors ranging from small countries in the third world regionto large industrialized countries. At present distribution covers around 90countries. In the early days a major breakthrough was to set up the North

American distribution through George Davy of Dormer Laboratories in

Toronto, Canada and long term valuable cooperation has been establishedwith Crawford Pharmaceuticals in the UK, Laboratoire Destaing in Franceand many other companies impossible to list in this limited section. Over thedecades, participation in numerous congresses such as ACDS/AAD, EADV,

World Congress of Dermatology, ISCD, ESCD, and many domestic congres-ses throughout the world has been thrilling as I have been fortunate to visitmany places and follow the scientific development in the area of contact der-matitis. I also remember interesting visits long ago to St Johns Hospital inLondon to meet Dr Etain Cronin, to Middle Road Hospital in Singaporeto meet Professor Che Leok Goh, Professor Howard Maibach at School ofMedicine USCF in San Francisco and Professor An Goossens at KatholiekeUniverstiteit, Leuven. Visits to Professor Jean-Pierre Lepoittevin and Dr ElenaGimenez-Arnau, Laboratoire de Dermato-Chimie, CHU, Strasbourg to learnhow to purify sesquiterpene lactones, to Odense University Hospital to learnmore about the allergen data bank of Professor Klaus E Andersen and se-

veral other clinics proved to be most valuable. What has given me specialsatisfaction is to have been able to inspire and share the knowledge in how toperform patch testing in clinics in countries such as Sri Lanka, Costa Rica,China and Macedonia.

The cooperation with important contact dermatitisgroups started with the

Photo

from

AAD

San

Francisco

2008

.


14/206

8


International Con-tact Dermatitis Group

(ICDRG) where I got toknow Jan E. Wahlberg,Jean-Marie Lachapelle,Howard Maibach, CheeLeok Goh, Iris Ale,Peter Elsner, SusannaFreeman, Ritsuko Hay-

akawa, Lasse Kanervaand Matti Hannuksela.The cooperation withthe European and En-

vironmental ContactDermatitis Research Group (EECDRG) providing material for multicen-ter studies has been most important as well as cooperation with the North

American Contact Dermatitis Group (NACDG) providing material for stu-dies of contact allergy frequency starting from 1992. My memberships inthe European and American Societies of Contact Dermatitis have furtherfacilitated the development of new products. Also cooperation with severaldomestic groups to provide national baseline series for haptens has beena priority and it has been a plea-sure to get to know many skillful

dermatologists in the field, toomany to mention by name inthis limited section. Material formany different multicenter stu-dies including perfume ingredi-ents, corticosteroids, sunscreens,pharmaceuticals and substancescausing photocontact allergy hasoriginated from our Swedishlaboratory and now current re-search is being done in coopera-tion with Professor Ann-ThereseKarlberg at Dermatochemistryand Skin Allergy, Department ofChemistry, Gothenburg Univer-sity to develop suitable test sub-

Photo from Nice 2011

Photo from EADV Lissabon 2011.


15/206

9


stances for important fragrance haptens.Since 1981 I have worked parallel to my two main colleagues in the produc-

tion of patch test products, Hermal in Germany who bought the Trolabbrand in 1981 represented by Theodor Schumacher, and Laila Malinenof Epitest in Finland producing the Finn Chamber. The competition hasbeen balanced and on ethical grounds which should be natural but cannotbe taken for granted.

Patch test chambers and general considerations

One day many years ago I said to myself, what are actually the basic require-ments for a test chamber as an aid in diagnosing contact allergy?Well, first of all it must be made of an inert material so that no reactiontakes place between the material in the chamber and the test preparationapplied on the surface of the chamber. Second, it must not elicit any al-lergic reaction in itself. Third, the carrier tape must be of such qualitythat it sticks well to the skin so that no reinforcement tape is needed and

it should not cause any irritation apart from rare cases of hyper-reactivityto tape material. Ideally, the carrier tape should be of a material such asthin elastic water resistant polyurethane to allow patients to take showers,exercise etc during the test period. Fourth, the test chamber must alsoprovide good occlusion onto the skin. The chamber should also keepthe substance within the chamber compartment to prevent from leakage.Ideally it should also be able to be loaded in advance to make patch testing

more efficient. With growing global awareness of environmental pollutionwe also recognized the importance of identifying materials for disposableproducts that would be recyclable. Now, what type of test chamber wasused in most clinics? The only chamber that existed apart from less usednon-chamber patches such as the Al Test designed by professor Fregert wasthe aluminum based Finn Chamber designed by professor Piril in 1975.Did it match the requirements? When ticking off the boxes I did not find

that the requirements were met by Finn Chambers. The environmentalconcern caused me to do a calculation based on a reasonable assumptionof use that resulted in the finding that aluminum corresponding to morethan 50,000 Coca Cola tins (33 cl) was just thrown away without recyclingand thus polluting the environment.The key development question was what improvements could be madein a new test chamber? First of all the material needed to be inert andrecyclable and polyethylene was therefore chosen. The form could perhapsbe changed from round to another shape. Some researchers had proposed


16/206


10

a square form to better distinguishallergic from irritant reactions so I

chose this form. The carrier tape Ichose was an extensively used hypoallergenic surgical tape from 3M. Wa-ter resistant polyurethane tapes weretried as well but for technical reasonsit was at that time difficult to finalizethis carrier tape. Also, as an additio-

nal feature I wanted the test unit tobe able to be preloaded at the clinicto save preparation time. The cham-ber should be made as an injection-moulded chamber. The test unit wasthen designed but the difficult task ofdesigning and manufacturing a pneu-

matic machine that could producethis chamber remained. To make a long story short the machine was fina-lized in 1993 after several difficulties during the process and the produc-tion of the IQ Chambers (IQ expressing Inert & Quadrate features) couldfinally be initiated.In my mind one should always be open to improvements to existing techni-ques and devices. So, after almost 10 years in production I reflected on the

features of the IQ Chambers and what improvements that could be made.The filter papers had to be inserted manually each time a test solutionshould be applied. The size of the tape unit was too big to allow severaltest series to be applied at the same time and the chamber material wasrather inflexible.One early morning, aninspiring and thrillingthought came into mymind; why not use lay-ers of laminated tapeswith an integrated filterpaper? The patient com-fort using such soft ma-terial must be far better.Also, now was the timeto make sure that the


17/206


11

chamber really did prevent leakage, sothe rim of the chamber should be equip-ped with an adhesive to make the cham-ber become a closed cell. The design ofthe IQ Ultra Chamber took place anda patent application was soon filed. Thedesign and production of the machine to

be used for serial production of the chambers was made and our teamendured a lot of struggle to arrive at the actual production of the cham-bers in 2003. The process of handling elastic tapes and the actual lamina-tion process proved to be far more complicated than first anticipated. Theimprovements were in place and now for the first time in the history ofpatch testing a smooth soft flexible chamber made of inert polyethylenefoam with double sided adhesive material, with an integrated filter paper

forming a test unit with a suitable small size, utilizing the same principleof preloading as the IQ Chamber and with an ability to secure the testpreparation within the chamber was available. The protection cover platewas made in such a way that each chamber with its content (if preloaded)was isolated in the airtight compartment of the cover.

After a few years inproduction I once againthought of how to overco-me the difficulties in usingthe thin elastic polyuretha-ne carrier tape to allow thepatients to go on with dailylife taking showers, per-forming heavy work andtaking exercise. The techni-cal aspects of handling a 25

Photo from ISCD Kyoto 2009.


18/206


12

micron thin film are intricate. Through a most valuable cooperation withour skillful developers, we were finally able to arrive at a converted film

that fulfilled the criteria. I thought this was the ultimate solution and theproduct was therefore branded IQ Ultimate with an aim to become thegold standard in this area.

General considerations

As a general reflection on patch test systems, the system needs to be veryflexible and new substances should be able to be added as soon as there

is a need depending on exposure and possible outbreaks of dermatitis ina certain area. One such example is the recent sofa dermatitis outbreakdue to Dimethyl fumarate found in anti-mold sachets hidden in a certainbrand of Chinese sofas. This is why legislation must not classify the patchtest substances into pharmaceuticals which then makes introduction intothe market a long term and costly issue thus limiting the range to only thefew most frequently found compounds eliciting contact allergy. The conse-

quence will also be that part of the range after some time will be obsoleteand several new important compounds will be lacking due to time and costfactors. The test substances are haptens and not full antigens and there-fore not able to induce an immune reaction as a stand alone compound.The full antigen (allergen) capability which depends on several biologicalfactors is the basis for this kind of classification which then should notbe relevant in this context. The traditionally used term allergen should

be replaced by hapten and the relevant classification should be MedicalDevice Class 1.

Reflections

Every day has been a day of learning, from continued research and coope-ration with colleagues within the actual science to legal matters and distri-bution agreements, writing patents, economy finance and tax, marketing

plans and material, company management, organization and staff manage-ment, machine construction and design, website development and muchmore, always new things to learn. My mission and dedication to the fieldof contact allergy has been, and will continue to be, to serve all those hardworking physicians with the diagnostic tools they need to make a correctdiagnosis, all for the benefit of the patients whom we are all ultimatelythere for.

How little did I know in the beginning of the 80's that a small side activitywould take me to the corners of the world, to see such beautiful places,


19/206


13

to meet so many bright and wonderful people in science, business andelsewhere, to experience such interesting cultures and to see and admire

Gods creation in nature in the most remarkable places.

*) Amended form published by J.M. Lachapelle in Giant Steps in PatchTesting, A Historical Memoir. Bo Niklasson, The Chemotechnique Story.2010, ISBN 978-0-9773571-2-3

Bo Niklasson

CEO, President and founder ofChemotechnique Diagnostics

Vellinge, Sweden, 2011


20/206

14


Chemotechnique DiagnosticsWebsite!

Visitwww.chemotechnique.se

Here, you can find more information on all availa-ble haptens, the national baseline series, patientrecords, Material Safety Data Sheets (MSDS) and

additional information about patch testing.

The Chemotechnique Diagnostics patch testproducts catalogue for 2012 is also available for down-

loading from our web site

Some of theses services require a free login account, soplease visitwww.chemotechnique.seto get yours.


21/206


15

Snapshots from our production


22/206

16


Change of terminologyThe traditionally used Allergen is replaced by Hapten starting from the 2010catalogue to avoid using an incorrect terminology.The only exception is Mx-21C; Dermatophagoides mix.

Haptens are substances incapable of inducing an immunologic reaction indiagnostic in vivo testing as a stand alone compound. A hapten needs a bindingto a protein to become an antigen capable of eliciting an allergic reaction andthis binding depends on individual biological factors in the patient being tested.

An allergen is defined as a full antigen with a capability to elicit an allergic reac-

tion during the patch test procedure. Some examples of common allergens arepollens, cat dander and dust mites.

INCI nomenclatureWe still continue to adapt to the terminology of the International Nomenclatureof Cosmetic Ingredients (INCI). The transition into these names is motivatedby the fact that it will be easier to find the ingredients on labels of cosmetic pro-ducts. The INCI names are shown as capital letters/upper case lettering in the

different tables or texts.Haptens & Skin MarkersChemotechnique Diagnostics takes pleasure in offering the widest range ofcommercially available haptens for patch testing now expanded to cover morethan 550 different preparations. In cooperation with various national Contact

Dermatitis Research Groups a number of country specific Baseline Series areavailable in addition to our normal range. The products are available throughour extensive network of distributors worldwide. You may download our elec-tronic catalogue in Adobe format from our web sitewww.chemotechnique.se. Patch testing, being the classical method for the diagnosis of contact aller-

gies, is an important tool when investigating contact dermatitis. This test beco-

Our Products


23/206


17

mes more reliable when using high quality standardised test substances. It is alsoimportant that the testing and interpretation of the result is performed by anexperienced physician.The raw material used is of the highest purity and treatedso that extremely small particles are formed and incorporated in the white petro-latum used as a vehicle.

The substances with a petrolatum vehicle are supplied in 5 ml polypropylenesyringes, while those in a liquid solution are supplied in 8 ml polypropylenedropper bottles. Haptens used infrequently should be stored in a cool place pro-tected from light. In accordance with their stability, we recommend that all sub-stances should be renewed according to the expiry stated on the labels of thehaptens. The white petrolatum used as a vehicle is from Penreco. As a rule, we

produce the purest and most homogeneous contamination-free haptens. We alsoprovide the special ChemoSkin Markerfor marking the patch test site. This conve-nient marker contains Methylrosaniline and Silver nitrate for prolonged stainingof the skin. For dark skin types or when a non staining ink is required we offerChemo Skin Marker-UVand a suitable UV-lamp for easy reading.

Chemo Nickel TestImportant tool to detect free nickel in metallic objects. One component productincorporating Dimethylglyoxime 1% in an ammoniacal solution for easy use

with the supplied cotton tips.1, 2

1) R.J.G. Rycroft, T. Menne, P.J. Frosch, Textbook of Contact Dermatitis,

2nd edition, (1995) ISBN 3-540-57943-5 Springer-Verlag Berlin, Heidelberg, New York.

2) Biesterbos J., Yazar K., Lidn C., Nickel on the Swedish market: follow-up 10 years

after entry into force of the EU Nickel Directive. Contact Dermatitis, 2010:63, p. 333-

339.

Test ChambersChemotechnique Diagnostics offers three typesof test chambers; IQ Chambers, IQ UltraChambers and IQ Ultimate Chambers. TheIQ Ultra Chambers combine the advantages ofusing inert square polyethylene foam chambersattached to a hypoallergenic tape. All test unitsoffers the feature of re-attaching the tape to a stiffplastic cover to prepare test units in advance. For

easy and fast loading of the test chambers use ourApplication Device. Reading plates are offered tofacilitate the reading of the test reactions.

Delivery on Request HaptensAn additional selection of Delivery on Request haptens (DOR) not shown in thecatalogue can be quoted upon your request.

New


24/206

18


ChemoteChnique DiagnostiCs

Chemotechnique Diagnostics is pleased to offerthe most advanced patch testing chambers unit.

New advantages-making patch testing easier, and moreconvenient for both the practitioner and the patients.


25/206

19


Features/Benefits

The IQ Ultra patch test unit has important advances:

Each chamber has a filter paper incorporated which eliminates addingloose filter papers.

The rim of each chamber has an adhesive layer to optimize adhesion tothe skin and to eliminate leakage. This makes IQ Ultraa closed-cellsystem enhancing occlusion and confining the test reaction within thechamber parameter.

The size of the IQ Ultrais small to allow the application of multiple

test units to patients backs. The chambers are made of thin and soft polyethylene foam materialthus making them even more comfortable for the patients.

The highest quality hypohaptenic surgical tape is used for the IQUltra. Each strip of 10 chambers ofIQ Ultrais attached to a pro-tective plastic cover with corresponding compartments which makes itpossible to re-attach the tape after advance filling of the chambers withthe haptens.

The IQ UltraApplication device makes advance filling of test sub-stances even easier. The device is specifically designed for the IQUltra. It is cost effective and saves nurses/technicians time, as theycan prepare test series up to two weeks prior to use. Volatile haptenssuch as acrylates should not be preloaded.

Product Information

IQ Ultra

is made of additive-free polyethylene plastic foam with a fil-terpaper incorporated.

IQ Ultra is supplied in units of 10 chambers (in 2 rows of 5 cham-bers/row) on a hypohaptenic non woven adhesive tape.

The tape with the chambers has a protective plastic cover with 10 cor-responding compartments. The cover makes it possible to re-attach thetape to the cover after advance filling of the chambers with haptens.

The volume of the chamber is 32 l and the inside area of the chamberis 64mm2.

The width of the tape is 52mm and the length is 118mm.

Packaging & Service

The IQ Ultrais supplied in cardboard boxes containing 100 units per box(100x10 chambers).

The IQ Ultra is available worldwide through the extensive network of

Chemotechnique Diagnostics distributors.


26/206

20


A 1. Put the IQ Ultra unit on a table,or use the IQ Ultras applicationplate (diagram A7). Take a firm gripon either the right or the left perfora-ted corner of the plastic cover. If youuse the IQ Ultras application plate,perform steps 2 & 3 and put the unitsin the plate by sliding them into thecompartments. The end of the unitwithout the perforated corners shouldbe inserted first. (See diagram A7)

2. Pull off the perforated corner of theplastic cover by bending it upwardsover the edge of the cover so that theperforation will brake.

3. Pull back the tape gently until allchambers are available for filling. The

tape should not be detached from thecover.

4. Apply the test preparation into theupper right chamber. Proceed with theother chambers until all are filled andthe test unit is ready for applicationonto the patients back. Rememberthat when applied to the back, theorder of the haptens will be left toright reversed, that is, the upper rightchamber will be no.1 at left.

5. Grip the end of the tape and theplastic cover (diagram A5). Press thetape to the back from below upwards.Remove the plastic cover (diagramA6). Instruct the patient to bend gent-ly forward when you apply the test

units. Press the tape with the palm ofyour hand for about 5 seconds (dia-gram A6). The pressure and heat willenhance adhesion. IQ Ultras has theunique feature in that the rim of eachchamber has an adhesive layer provi-ding optimal adhesion of the chamberonto the skin. Therefore, no additio-nal reinforcement of the tape unit isneeded and leakage from the cham-ber is eliminated. The patient may per-

form normal work as well as light exer-cise during the test application.

B. When applying liquid haptens, applya drop of the test solution to the filterpaper in the chamber (about 25 l).The amount should be just enough toproperly moisten the filter paper. Donot prepare liquid solutions in advan-

ce for storage.

C. When applying the test patches onthe patient, use if possible the upperpart of the patients back, and avoid toapply patches to the midline and thescapula. If several test series are app-lied, 2 horizontal rows of 4-5 units perrow can be applied across the back.In some cases other areas of the bodylike the upper part of the arms may beused. If the patients skin is oily you canclean it gently with some ethanol.

D. Mark to the left of the tape thefirst and the 5th chamber or the fourcorners of each unit with the special

Chemotechnique Skin Marker. Makea record on a record form of the num-bers and names of each hapten star-ting with no.1 of the left upper patchand going down and continue then tothe right until all patches are recorded.For record forms, visit our website

www.chemotechnique.se where readyforms are available under the section

record forms.

E. Give the patient a test informationsheet. Provide the patient a copy ofInitial Patient Instruction Sheet, cove-ring procedural information, dos anddonts, care and cautions (available onour website).

Patch Test Technique IQ Ultra


27/206


21

A 12

1

2

Pull and

bend corner

A 4

A 3

Tape wi thIQ Ultra

Plastic cover

Removal of the test unit

A 6

A 8

Application plate

A 7

A 5

F. The patches should be removed after

48 hours. When removing the patches it

is very important to detach the units ina rapid diagonal direction to minimizepatient discomfort (diagram A8).

Visual imprints on the skin from eachchamber + a slight erythema from theframes should be visible as a sign of goodocclusion. The material of the test unitsare recyclable and unlike aluminium con-taining material environmentally safe.

Reading of the test is performed atday 3 or 4 after test application. At day3, a weak erythema from the framesmight be present in patients with sensi-tive skin. Some clinics prefer to add aninitial reading when the tape units are

removed. If this is made, allow initialskin irritation from the backing tape andthe foam frame tape to subside, as wellas reduction of the visual imprint onthe skin due to the high skin occlusionof the chambers. Use the IQ ULTRAReading Plate to facilitate the reading. Inmany instances, a second reading a weekafter the application is of value. Theback should not be rubbed by e.g. a bras-siere or be scratched in the case of posi-tive reactions. The patient should not

take any cortisone medication duringthe test and avoid exposure of the backto the sun.


28/206

22


3. Immediately after removal.

Visual chamber imprints, excellentocclusion.

2. Removal of units.A rapid diagonalmotion will minimize patient discomfort.

4. One hour after removal.

Imprints gone, slight erythema from tape.

1. Application. Size permits maximumunits on back. Normally no reinforce-ment tape is needed.

Photo

bycourtesy

ofDr.

Ra

doslaw

Spiewak

For the interpretation of the test result the followingscheme can be used:IR Irritant reaction.

Discrete patchy erythema without infiltration.

+++ Extreme positive reaction

-Coalescing vesicles-Bullous or ulcerative reaction

++ Strong positive reaction

-Erythema -Papules-Infiltration -Discrete vesicles

+ Weak positive reaction-Erythema -Papules-Infiltration

?+ Doubtful reaction.

-Faint macular -No infiltration

-Homogenous erythema


29/206


23

ChemoteChniqueDiagnostiCs

Water resistant, transparentand elastic!

"The ultimate solution for patch testing"

Underd

evelo

pment


30/206

24


For efficient and accuratePatch Testing

developed by

IQ ChamberIQ ChamberThe Original

Plastic Chamber

ChemoteChniqueDiagnostiCs


31/206

25


Chemotechnique Diagnostics has the great pleasure of introducing the IQChamber patch test unit.

Feature

The IQ Chamber is an Inert Quadrate & Ideal Quick test chamber unit.The chambers are unique, in the fact that each test unit of 10 chambers isattached to a stiff plastic cover with 10 compartments corresponding to eachof the 10 chambers on the tape. The cover makes it possible to re-attach thetape to the cover after filling the chambers with hapten preparations. Thisimportant feature facilitates and reduces significantly the time of test appli-

cation because the nurse or assistant can prepare many test units in advan-ce. The IQ Chamber Application device makes advance filling of test sub-stances even easier. The device is specifically designed for the IQ Chamber.It is cost effective and saves nurses/technicians time, as they can prepare testseries up to two weeks prior to use. Volatile haptens such as acrylates shouldnot be preloaded.

Product Information

The IQ chamber is made of additive free polyethylene plasticTheIQchambersaresuppliedinunitsof10chambers(in2rowsof5

chambers/row) on a hypohaptenic non woven adhesive tape.

Thetapewiththechambersisprotectedbyastiffplasticcoverwith10compartments that correspond to the chambers on the tape.

Thevolumeofthechamberis65landtheinsideareaofthechamberis9x9 mm (81mm2).

Thedistancebetweenthechambersis12mmintherowand20mmbet-ween the rows.

Thewidthofthetapeis68mmandthelengthis142mm.

Packaging & Service

IQ Chambers are delivered in cardboard boxes containing 100 units perbox.

IQ Chambers are available worldwide through the extensive neworkof Chemotechnique Diagnostics agents already distributing theChemotechnique patch test haptens.


32/206

26


A 1. Put the IQ unit on a table, or use theChemotechnique application device.Take a firm grip on either the right orthe left perforated corner of the plasticcover.

2. Pull off the perforated corner of theplastic cover by bending it downwardsover the edge of the cover so that theperforation will brake.

3. Pull back the tape gently until allchambers are available. The tape shouldnot be loosened from the cover.

4. Apply the test preparation into theupper right chamber. Proceed with theother chambers until all are filled andthe test unit is ready for applicationonto the patients back. Remember that

when applied to the back, the order ofthe haptens will be left to right reversed,that is, the upper right chamber will beno.1 at left.

5. Grip the end of the tape and theplastic cover (picture A5). Press thetape to the back from below upwards.Remove the plastic cover (picture

A6). For maximum adhesion press thepalm of the hand to the tape for about5 seconds. Using IQ Chambers, a bigadvantage is that you can prepare seve-ral test units in advance and store themin your refrigerator in a closed plastic

bag up to 1-2 weeks. If you wish to adoptthis method, put the tape back onto the

plastic cover and mark the unit with thename and numbers of the test series(e.g. Standard 1-10).B. When applying liquid haptens, applya drop of the test solution to the filterpaper in the chamber (about 25 l). Theamount should be just enough to pro-perly moisten the filter paper. Press thefilter paper down into the chamber witha pair of tweezers. Do not prepare liquidsolutions in advance for storage.

C. When applying the test patches onthe patient, use if possible the upperpart of the patients back, and avoid toapply patches to the midline and thescapula. In some cases other areas of thebody like the upper part of the arms maybe used. If the patients skin is oily youcan clean it gently with some ethanol.Instruct the patient to bend gently for-

ward when you apply the test units.

D. Mark to the left of the tape the firstand the 5th chamber with the specialChemo Skin Marker. Only for special diffi-cult cases you will need to apply extra rein-forcement tape. Make a record on a recordform of the numbers and names of eachhapten starting with no. 1 of the left upperpatch and going down and continue then

to the right until all patches are recorded.The most convenient way of making such

Patch Test Technique IQ Chamber

Chemotechnique Diagnostics haptens can be applied to all types of patchtest plasters. However, the test chamber of choice is a chamber made of inertpolyethylene plastic and the chamber recommended is the ChemotechniqueIQ Chamber. The use of polyethylene plastic is recommended to avoid sidereactions caused by material such as aluminium metal. Aluminium can elicitallergic reactions to the material of the test chamber itself as well as catalyzereactions of the test preparation and also absorb the haptens to the surfaceof the metal.

Test ProcedureThe IQ chambers are supplied in units of 10 chambers on a hypohaptenicnon woven adhesive tape. The tape with the chambers is protected by a stiffplastic cover with 10 compartments that correspond to the chambers on thetape.


33/206


27

For the interpretation of the test result the following scheme can be used;- Negative reaction? Doubtful reaction+ Weak reaction (non-vesicular)++ Strong reaction (oedematous or vesicular)+++ Extreme reaction (ulcerative or bullous)IR Irritant reactionNT Not tested

Photopatch tests are graded similarly by just adding the prefix Ph.The relevance of the reaction should be assessed and recorded as present,past or unexplained.

In doubtful cases, a repeated open application test (ROAT) is recommen-ded. The test material is then applied to the skin of the antecubital spaceof the upper arm twice daily for a week. In most cases of contact allergy, anitching papular dermatitis will develop within a few days.

record forms is to use the Chemotechniqueweb site atwww.chemotechnique.se.E. The patches should be removed after

48 hours. Reading of the test is perfor-med 72 hours after the test application.In many instances, a second reading a

week after the application is of value.To facilitate the reading, the special IQChambers Reading Plate could be used.

During the time the patches remain onthe back the patient should not shower,perform hard work or do exercise that

will result in sweating. The back shouldnot be rubbed by e.g. a brassiere or bescratched in the case of positive reac-tions. The patient should not take anycortisone medication during the test andavoid exposure of the back to the sun.


34/206

28


IQ ChamberYour choice for patch testing

Inert Quadrate chamber with

Improved Quality makes it the

Ideal & Quick patch test unit.


35/206


29

General information & referencesfor IQ, IQ-Ultra and IQ-Ultimate

The basic requirements for a patch test chamber involves using an inertmaterial applied to a hypoallergenic tape providing good occlusion andfixation of the test unit to the skin.

The material of IQ-Chamers is inert, additive free polyethylene andIQ-Ulta/IQ Ultimate is inert, additive free polyethylene foam and theopening of the chamber is square to make it easier to differentiate between

allergic and irritant reactions. Undesired side effects in the form of allergicreactions to the test unit itself are avoided due to the chemical stability ofthe polyethylene plastic.1-24 The effect of reactive test substances on the testchamber which may result in secondary toxic reactions during the patch test,is also avoided due to polyethylenes chemical resistance to these types ofsubstances.25-31 By using inert plastic material such as polyethylene, the riskof inactivation, modification and absorption of the hapten during contact

with the surface of the test chamber is avoided. 32-33, 35 Considering these

facts, the importance and advantages of using chambers made of inert plasticmaterial has been demonstrated.31,34, 36-42

Patents granted in several countries

References1. Hall A F. Occupational contact dermatitis among aircraft workers.

JAMA 1944:125:179-185.2. Clemmensen O, Knudsen H E. Contact sensitivity to aluminum in apatient hyposensitized with aluminum precipitated grass pollen. ContactDermatitis 1980:6:303-308.3. Fisher T, Rystedt I. A case of contact sensitivity to aluminum. ContactDermatitis 1982:8:343.4. Kotovirta M-L, Salo O P, Visa-Tolvanen K. Contact sensitivity to alumi-num. Contact Dermatitis 1984:11:135.

5. Meding B, Augustsson A, Hansson C. Patch test reactions to aluminum.Contact Dermatitis 1984:10:107.6. Fawcett H A, McGibbon D, Cronin E. Persistent vaccination granulomadue to aluminum sensitivity. Br J Dermatol 1985:113 (suppl. 29):101-102.7. Veien N K, Hattel T, Justesen O, Nrholm A. Aluminum allergy. ContactDermatitis 1986:15:295-297.8. Bhler-Sommeregger K, Lindemayr H. Contact sensitivity to alumi-num. Contact Dermatitis 1986:15:278-281.

9. Cox N H, Moss C, Forsyth A. Allergy to non-toxoid constituents of vacci-nes and implications for patch testing. Contact Dermatitis 1988:18:143-146.


36/206

30


10. Castelain P Y, Castelain M, Vervloet D, Garbe L, Mallet B. Sensitizationto aluminum by aluminum-precipitated dust and pollen extracts.Contact Dermatitis 1988:19:58-60.11. Tosti A, Vincenzi C, Peluso A M. Accidental diagnosis of aluminumsensitivity with Finn Chambers. Contact Dermatitis 1990:23:48-49.12. Cosnes A, Flechet M-L, Revuz J. Inflammatory nodular reactionsafter hepatitis B vaccination due to aluminum sensitization. ContactDermatitis 1990:23:65-67.13. Kaaber K, Nielsen A O, Veien N K. Vaccination granulomas and alu-minum allergy: course and prognostic factors. Contact Dermatitis1992:26:304-306.14. Nielsen AO, Kaaber K, Veien NK. Aluminum allergy caused by DTP

vaccine. Ugeskr Laeger. 1992 Jun 29;154(27):1900-1. Danish.15. Veien N K, Hattel T, Laurberg G. Systemically aggravated contactdermatitis caused by aluminum in toothpaste. Contact Dermatitis1993:28:199-200.16. Dwyer C M, Kerr R E. Contact allergy to aluminum in 2 brothers.Contact Dermatitis 1993:29:36-38.17. Lopez S, Pelaez A, Navarro LA, Montesinos E, Morales C, Carda C.

Aluminium allergy in patients hyposensitized with aluminium-precipita-ted antigen extracts. Contact Dermatitis. 1994 Jul;31(1):37-40.18. Barbaud A, Schmutz JL, Mougeolle JM. Cutaneous immunoallergicreactions caused by vaccines. Ann Dermatol Venereol. 1995;122(3):129-38. Review. French.19. Veien NK. Routine patch testing with AlCl3. Contact Dermatitis. 1996

Aug;35(2):126.20. Helgesen AL, Austad J. Contact urticaria from aluminium and nickel

in the same patient. Contact Dermatitis. 1997 Dec;37(6):303-4.21. Bajaj AK, Gupta SC, Pandey RK, Misra K, Rastogi S, Chatterji AK.

Aluminium contact sensitivity. Contact Dermatitis. 1997 Dec;37(6):307-8.22. Skowron F, Grezard P, Berard F, Balme B, Perrot. Persistent nodules atsites of hepatitis B vaccination due to aluminium sensitization. ContactDermatitis. 1998 Sep;39(3):135-6.23. Peters T, Hani N, Kirchberg K, Gold H, Hunzelmann N, Scharffetter-Kochanek K. Occupational contact sensitivity to aluminium in a machine

construction plant worker. Contact Dermatitis. 1998 Dec;39(6):322-3.24. Purello-DAmbrosio F, Gangemi S, Minciullo PL, Lombardo G, RicciardiL, Isola S, Merendino RA.Aluminium allergy in a patient with occupa-tional contact dermatitis. Allergol Immunopathol (Madr). 2000 Mar-

Apr;28(2):74-5.25. Frosch P, Kligman A. The Duhring Chamber. Contact Dermatitis1979:5:73-81.26. Kalveram K-J, Rapp-Frisk C, Sorck G. Misleading patch test results

with Aluminum Finn Chambers and mercury salts. Contact Dermatitis


37/206

31


1980:6:507-508.27. Fischer T, Maibach H. Aluminum in Finn chambers reacts with cobalt

and nickel salts in patch test materials. Contact dermatitis 1985:12:200-202.28. Lachapelle J M, Douka M A. An evaluation of the compatibility bet-

ween Aluminum Finn chambers and various mercurials dissolved inwater or dispersed in petrolatum. Dermatosen 1985:33:12-14.29. Lindeemayr H, Becerano S. Interaction of mercury compounds andaluminum. Contact Dermatitis 1985:13:274.30. Kubo Y, Nonaka S, Yoshida H. False positive reaction to patch testing

with aqueous mercuric chloride in an aluminum Finn Chamber. ContactDermatitis 1992:26:136-137.31. Kubo Y, Anan S, Nonaka S, Yoshida H. Does patch testing with ammo-niated mercury in a Finn Chamber give a false positive reaction? ContactDermatitis 1992:27:118-119.32. Bjrkner B, Niklasson B. Influence of the vehicle on elicitation of con-tact allergic reactions to acrylic compounds in the guinea pig. ContactDematitis 1984:11:268-278.33. Bruze M, Bjrkner B, Lepoittevin J-P. Occupational allergic contactdermatitis from ethylcyanoacrylate. Contact Dermatitis 1995:32:156-159.34. Fischer T. Design Considerations for patch testing. American Journalof Contact Dermatitis 1994:5:70-75.35. Budavari S. Aluminum & Aliminium Oxide. The Merck Index, 11th edi-tion, Rahway, NJ., USA, Merck & Co., Inc. 1989, page 54, 58.36. Guin J. (ed). Practical Contact Dermatitis. Niklasson B. Chapter 51,

Appendix A. McGraw-Hill Inc. 1995.37. Kanerva L, Elsner P, Wahlberg J.E, Maibach H.I. (ed). Handbook ofOccupational Dermatology. Niklasson B. Chapter 184 Springer Verlag 2000.38. Netterlid E, Hindsn M, Bjrk J, Ekqvist S, Gner N, Henricson KA,Bruze M. There is an association between contact allergy to aluminium andpersistent subcutaneous nodules in children undergoing hyposensitizationtherapy. Contact Dermatitis. 2009 Jan;60(1):41-9.39. Brodbaker E, Pratt M. Contact sensitivity to aluminum. J Cutan MedSurg. 2009 Jul-Aug;13(4):226-9.40. Garg S, Loghdey S, Gawkrodger DJ. Allergic contact dermatitis from alu-minium in deodorants. Contact Dermatitis. 2010 Jan;62(1):57-8.41. Garg S, Loghdey S, Gawkrodger DJ. Allergic contact dermatitis from alu-minium in deodorants. Contact Dermatitis. 2010 Jan;62(1):57-8.42. Beveridge MG, Polcari IC, Burns JL, Adler A, Hendrickson B, Stein SL.Local Vaccine Site Reactions and Contact Allergy to Aluminum. PediatrDermatol. 2011 Aug 19. doi: 10.1111/j.1525-1470.2011.01541.x.


38/206

32


Patch Test Products

Hapten series Code Page

European Baseline Series S-1000 34-35International Comprehensive Baseline Series ICB-1000 36-39Bakery Series B-1000 40Corticosteroid Series CS-1000 41Cosmetic Series C-1000 41-43

Cutaneous Adverse Drug Reaction Series CAD-1000 43-44Dental Screening DS-1000 44-45Dental Materials Patients DMP-1000 45Dental Materials Staff DMS-1000 46Epoxy Series E-1000 46Fragrance Series F-1000 46-48Hairdressing Series H-1000 48-49

International Standard Series IS-1000 49-50Isocyanate Series I-1000 51Leg Ulcer Series LU-1000 51-52Medicament Series ME-1000 52Metal Series MET-1000 53-54(Meth) Acrylate Series MA-1000 54

Adhesives, Dental & Other

(Meth) Acrylate Series MN-1000 54-55Nails-Artificial(Meth) Acrylate Series MP-1000 55-56

Printing

Oil & Cooling Fluid Series O-1000 56-57Photographic Chemicals Series P-1000 57Plant Series PL-1000 58Plastics & Glues Series PG-1000 58-59Rubber Additives Series R-1000 59-60Scandinavian Photo Patch SP-1000 60-61Shoe Series SH-1000 61-62Sunscreen Series SU-1000 62-63Textile Colours & Finish TF-1000 63-64

Various Haptens V-1000 64-66Supplemental Haptens SA-1000 66-67


39/206


33

Other items Code Page

Application Device forIQ Chamber AP 17IQ Ultra & IQ Ultimate AP-U 17

Chemo Skin Marker- Slim SMS 16-17

Chemo Skin Marker- UV SMUV 16-17Chemo Skin Marker- Regular SM 16-17IQ Ultra Chambers; 100 x 10 chambers IQ-U 18-22IQ Ultimate Chambers; 100 x 10 chambers IQ-UL 23IQ Chambers; 100 x 10 chambers IQ-100 24-27Chemo Nickel Test (Dimethylglyoxime) NT 17Plastic Hapten Tray TrayReading Plate for

IQ Chamber RPIQ Ultra & IQ Ultimate RP-UIQ Ultra & IQ Ultimate (Plus)New RP-P 17

Ultraviolet Lamp (handheld) UV-Lamp 16-17

Upon request;Belgium Baseline, British Baseline, Finnish Baseline, Korean Baseline,North American Baseline Series, North American Photopatch, SwedishBaseline, Hungarian Baseline, Indian Baseline. Composition and test recordforms are available for all our series on the websitewww.chemotechnique.se. Due to frequent changes in the national base-line series, these are not listed in the printed catalogue.

A great number of Delivery on Request haptens (DOR) not shown in thecatalogue can be quoted upon your request.


40/206

34


Compound Conc. Veh. Conc. Art.nr.%(w/w) molality(m)

European Baseline Series S-1000

1. Potassium dichromate 0.5 pet 0.017 P-014A2. p-PHENYLENEDIAMINE (PPD) 1.0 pet 0.092 P-0063. Thiuram mix 1.0 pet Mx-01

-Tetramethylthiuram monosulfide (TMTM) 0.25 0.012 T-006-Teramethylthiuram disulfide (TMTD) 0.25 0.010 T-005

-Tetraethylthiuram disulfide (TETD) 0.25 0.008 T-002-Dipentamethylenethiuram disulfide (PTD) 0.25 0.008 D-019

4. Neomycin sulfate 20.0 pet N-0015. Cobalt(II)chloride hexahydrate 1.0 pet 0.042 C-017A6. Benzocaine 5.0 pet 0.303 B-0047. Nickel(II)sulfate hexahydrate 5.0 pet 0.190 N-002A8. Clioquinol 5.0 pet 0.164 C-015

9. COLOPHONIUM 20.0 pet C-02010. Paraben mix 16.0 pet Mx-03C-METHYLPARABEN 4.0 0.263 M-012-ETHYLPARABEN 4.0 0.241 E-010-PROPYLPARABEN 4.0 0.222 P-020-BUTYLPARABEN 4.0 0.206 B-020

11. N-Isopropyl-N-phenyl-4-phenylenediamine(IPPD) 0.1 pet 0.004 I-004

12. LANOLIN ALCOHOL 30.0 pet W-00113. Mercapto mix 2.0 pet Mx-05A

-N-Cyclohexyl-2-benzothiazyl sulfenamide 0.5 0.019 C-023-2-Mercaptobenzothiazole (MBT) 0.5 0.030 M-003-Dibenzothiazyl disulfide (MBTS) 0.5 0.015 D-003-2-(4-Morpholinylmercapto)benzothiazol(MOR) 0.5 0.020 M-016

14. Epoxy resin, Bisphenol A 1.0 pet E-002

15. MYROXYLON PEREIRAE RESIN* 25.0 pet B-00116. 4-tert-Butylphenolformaldehyde resin 1.0 pet B-02417. 2-Mercaptobenzothiazole (MBT) 2.0 pet 0.120 M-003A18. FORMALDEHYDE 1.0 aq 0.333 F-002A19. Fragrance mix I* 8.0 pet Mx-07

-CINNAMYL ALCOHOL 1.0 0.075 C-013-CINNAMAL 1.0 0.076 C-014

* Emulsifier: SORBITAN SESQUIOLEATE 5%


41/206


35

-Hydroxycitronellal 1.0 0.059 H-008-AMYL CINNAMAL 1.0 0.049 A-014-GERANIOL 1.0 0.065 G-001-EUGENOL 1.0 0.061 E-016-ISOEUGENOL 1.0 0.061 I-002-Oakmoss absolute 1.0 O-001

20. Sesquiterpene lactone mix 0.1 pet MX-18-Alantolactone 0.033 A-003-Dehydrocostus lactone 0.033 D-056-Costunolide 0.033 C-039

21. QUATERNIUM-15 (Dowicil 200) 1.0 pet 0.040 C-007A22. 2-Methoxy-6-n-pentyl-4-benzoquinone 0.01 pet 0.0005 M-00823. METHYLISOTHIAZOLINONE +

METHYLCHLORO-ISOTHIAZOLINONE 0.01 aq C-009A

24. Budesonide 0.01 pet 0.0002 B-033B25. Tixocortol-21-pivalate 0.1 pet 0.002 T-031B26. METHYLDIBROMO GLUTARONITRILE 0,5 pet 0.019 D-049E27. Fragrance mix II 14,0 pet Mx-25

-Lyral 2,5 0,119 L-003-CITRAL 1,0 0,066 C-036-FARNESOL 2,5 0,113 F-004

-CITRONELLOL 0,5 0,030 C-037-Hexyl cinnamic aldehyde 5,0 0,231 H-025-COUMARIN 2,5 0,171 C-038

28. Lyral 5,0 pet 0,238 L-003

Revised March 2008

It is strongly recommended to make an additional reading of the test onday 7.

References: 1. M. Isaksson, F.M. Brandao, M.Bruze, A.Goossens. Recommendationto include budesonide and tixocortol privalate in the european standard series.

Contact dermatitis 2000, 43, 41-42.2. Maureen J. Jonker & Derk P. Bruynzeel. The outcome of anadditional test reading on days 6 or 7. Contact dermatitis 2000, 42, 330-335.

3. Recommendation to include Fragrance mix II and hydroxyisohexyl 3-cyclohexenecarboxaldehyde (Lyral) in the European baseline patch test series

Bruze M, Andersen KE, Goossens A.

Accepted for publication in Contact DermatitisVarious national baseline series developed by the national contact

dermatitis research groups are also available on request.



42/206

36


1. Benzocaine* 5.0 pet 0.303 B-0042. 2-Mercaptobenzothiazole (MBT) 1.0 pet 0.060 M-003B3. COLOPHONIUM* 20.0 pet C-0204. p-PHENYLENEDIAMINE (PPD)* 1.0 pet 0.092 P-0065. IMIDAZOLIDINYL UREA 2.0 pet 0.052 I-001A

6. CINNAMAL 1.0 pet 0.075 C-0147. Amerchol L 101 50.0 pet A-0048. Carba mix 3.0 pet Mx-06

-1,3-Diphenylguanidine 1.0 0.047 D-022-Zinc diethyldithiocarbamate (ZDC) 1.0 0.028 Z-003-ZINC DIBUTYLDITHIOCARBAMATE(ZBC) 1.0 0.021 Z-002

9. Neomycin sulfate* 20.0 pet N-00110. Thiuram mix* 1.0 pet Mx-01-Tetramethylthiuram monosulfide (TMTM) 0.25 0.012 T-006-Teramethylthiuram disulfide (TMTD) 0.25 0.010 T-005-Tetraethylthiuram disulfide (TETD) 0.25 0.008 T-002-Dipentamethylenethiuram disulfide (PTD) 0.25 0.008 D-019

11. Clobetasol-17-propionate 1.0 pet C-02812. Ethylenediamine dihydrochloride 1.0 pet 0.075 E-00513. Epoxy resin, Bisphenol A* 1.0 pet E-00214. QUATERNIUM-15 (Dowicil 200)* 2.0 pet 0.080 C-007B15. 4-tert-Butylphenolformaldehyde resin* 1.0 pet B-02416. Mercapto mix 1.0 pet Mx-05B

-N-Cyclohexyl-2-benzothiazyl sulfenamide 0.25 0.009 C-023-2-Mercaptobenzothiazole (MBT) 0.25 0.015 M-003-Dibenzothiazyl disulfide (MBTS) 0.25 0.008 D-003

-2-(4-Morpholinylmercapto)benzothiazol(MOR) 0.25 0.010 M-016

17. N-Isopropyl-N-phenyl-4-phenylenediamine(IPPD)* 0.1 pet 0.004 I-004

18. Potassium dichromate 0.25 pet 0.008 P-014B19. MYROXYLON PEREIRAE RESIN*,** 25.0 pet B-00120. Nickel(II)sulfate hexahydrate 2.5 pet 0.095 N-002B


International ComprehensiveBaseline Series ICB-1000

* Also present in European Baseline Series

** Emulsifier: SORBITAN SESQUIOLEATE 5%


43/206

37


21. DIAZOLIDINYL UREA 1.0 pet 0.035 D-044C22. TOCOPHEROL 100% T-03623. Bacitracin 20.0 pet 0.140 B-032B24. Mixed dialkyl thiourea 1.0 pet Mx-24

-N,N-Diethylthiourea 0.5 D-039-N,N-Dibutylthiourea 0.5 D-038

25. DISPERSE ORANGE 3 1.0 pet D-032

26. Paraben mix 12.0 pet Mx-03A-METHYLPARABEN 3.0 0.197 M-012-ETHYLPARABEN 3.0 0.181 E-010-PROPYLPARABEN 3.0 0.167 P-020-BUTYLPARABEN 3.0 0.155 B-020

27. METHYLDIBROMO GLUTARO-NITRILE* 0.5 pet 0.019 D-049E

28. Fragrance mix I*,** 8.0 pet Mx-07-CINNAMYL ALCOHOL 1.0 0.075 C-013-CINNAMAL 1.0 0.076 C-014-Hydroxycitronellal 1.0 0.059 H-008-AMYL CINNAMAL 1.0 0.049 A-014-GERANIOL 1.0 0.065 G-001-EUGENOL 1.0 0.061 E-016-ISOEUGENOL 1.0 0.061 I-002-Oakmoss absolute 1.0 O-001

29. GLUTARAL 0,5 pet G-003B30. 2-BROMO-2-NITROPROPANE-1,3-DIOL 0.5 pet 0.026 B-015B31. Sesquiterpene lactone mix* 0.1 pet MX-18

-Alantolactone 0.033 A-003-Dehydrocostus lactone 0.033 D-056-Costunolide 0.033 C-039

32. THIMEROSAL (Merthiolate) 0.1 pet 0.003 T-007

33. PROPOLIS 10.0 pet P-02234. BENZOPHENONE-3 10.0 pet 0.440 H-014C35. CHLOROXYLENOL (PCMX) 1.0 pet 0.064 C-010B36. Ethyleneurea, melamine formaldehyde mix 5.0 pet 0.116 Mx-16

(Fix.Ac)**-Ethyleneurea 4.0 D-012-Melamine formaldehyde 1.0 M-001





44/206


45/206


39

65. Disperse Blue mix 106/124 1.0 pet Mx-26-Disperse Blue 106 0.5 D-040-Disperse Blue 124 0.5 D-041

66. Compositae mix II 5.0 pet Mx-29A-TANACETUM VULGARE EXTRACT 1.0 T-033-ARNICA MONTANA EXTRACT 0.5 A-024-Parthenolide 0.1 P-029-ANTHEMIS NOBILIS EXTRACT 1.2 C-029-Chamomilla Recutita(German Chamomill) 1.2 C-051-ACHILLEA MILLEFOLIUM EXTRACT 1.0 A-025

67. Lidocaine 15.0 pet L-002B68. Fusidic acid sodium salt 2.0 pet 0.037 F-00369. Dibucaine hydrochloride 2.5 pet D-005B70. Benzoylperoxide 1.0 pet 0.041 B-007

71. ISOAMYL p-METHOXYCINNAMATE 10.0 pet 0.403 I-00972. Lyral* 5.0 pet 0.238 L-00373. Octyl salicylate 5.0 pet O-00774. BENZALKONIUM CHLORIDE 0.1 aq B-02775. Amidoamine 0.1 aq A-02976. COCAMIDOPROPYL BETAINE 1.0 aq C-01877. FORMALDEHYDE* 1.0 aq 0.333 F-002A

78. METHYLISOTHIAZOLINONE +METHYLCHLORO-ISOTHIAZOLINONE* 0.01 aq C-009A

79. PROPYLENE GLYCOL 30.0 aq 3.942 P-019B80. Dimethylol dihydroxy ethylene urea

(Fix. CPN) 4.5 aq 0.253 D-012

New January 2011

In the year of 2011 we included a new routine screening series named InternationalComprehensive Baseline Series (ICB-1000) containing 80 haptens. This consists of a

selection of haptens based on the experience from many years of studies of

frequencies of contact allergy performed by the North American Contact Dermatitis

Group (NACDG). Chemotechnique Diagnostics has cooperated with the NACDG by

supplying haptens to the group for research during a period of 17 years. We wanted to

make available a larger selection of haptens for routine screening and started to offer




46/206

40


this series to our North American customers. Now this selection will be available as

ICB-1000 to our other customers worldwide.

We believe this series will be an important addition for those physicians who eitherdo not have a domestic Baseline series or want to go beyond the various baseline

series offered. The experience has been that a larger routine screening series will pro-

duce a higher yield of positive reactions and contribute to a better diagnosis.1,2

Patch-test results of the North American Contact Dermatitis Group 2005-2006.

1) Dermatitis. 2009 May-Jun;20(3):149-60.

Zug KA, Warshaw EM, Fowler JF Jr, Maibach HI, Belsito DL, Pratt MD,Sasseville D, Storrs FJ, Taylor JS, Mathias CG, Deleo VA, Rietschel RL, Marks J

2) Allergens of New and Emerging Significance

Christen M. Mowad, MD

Dermatology Nursing. 2006;18(6):545-548. 2006 Jannetti Publications, Inc.

Bakery Series B-1000

1. Vanillin 10.0 pet 0.657 V-0012. EUGENOL 2.0 pet 0.122 E-0163. ISOEUGENOL 2.0 pet 0.122 I-0024. SODIUM BENZOATE 5.0 pet 0.347 S-001

5. BHT 2.0 pet 0.091 D-0066. Menthol 2.0 pet 0.128 M-0027. CINNAMYL ALCOHOL 2.0 pet 0.149 C-0138. CINNAMAL 1.0 pet 0.151 C-0149. 2-tert-Butyl-4-methoxyphenol (BHA) 2.0 pet 0.111 B-02210. trans-Anethole 5.0 pet 0.337 A-01511. SORBIC ACID 2.0 pet 0.178 S-003

12. Benzoic acid 5.0 pet 0.409 B-00513. PROPIONIC ACID 3.0 pet 0.405 P-01814. Octyl gallate 0.25 pet 0.009 O-00215. DIPENTENE (oxidized) 1.0 pet 0.073 D-02016. AMMONIUM PERSULFATE 2.5 pet 0.110 A-01117. Benzoylperoxide 1.0 pet 0.041 B-00718. PROPYL GALLATE 1.0 pet 0.047 P-02119. DODECYL GALLATE 0.25 pet 0.007 D-042



47/206


48/206


49/206

43


51. SHELLAC 20.0 alc S-01552. TOCOPHERYL ACETATE 10.0 pet T-037B53. Turpentine peroxides 0.3 pet T-024B54. METHYLISOTHIAZOLINONE 0.2 aq M-035B55. Musk mix 3.0 pet Mx-10B

-Musk xylene 1.0 0.034 M-021-Musk moskene 1.0 0.036 M-019-MUSK KETONE 1.0 0.034 M-018

56. OLEAMIDOPROPYL DIMETHYLAMINE 0.1 aq 0.003 O-005

Revised January 2012

Cutaneous AdverseDrug Reaction series CAD-1000

1. Penicillin G, potassium salt 10.0 pet 0.268 P-0312. Amoxicillin trihydrate 10.0 pet 0.274 A-0303. Dicloxacillin sodium salt hydrate 10.0 pet 0.196 D-0584. Cefotaxim sodium salt 10.0 pet 0.210 C-0405. Doxycycline monohydrate 10.0 pet 0.216 D-0596. Minocycline hydrochloride 10.0 pet 0.202 M-0297. Erythromycin base 10.0 pet 0.136 E-024

8. Spiramycin base 10.0 pet 0.119 S-0129. Clarithromycin 10.0 pet 0.134 C-04110. Pristinamycin 10.0 pet P-03211. Cotrimoxazole 10.0 pet 0.184 C-04212. Norfloxacin 10.0 pet 0.313 N-00713. Ciprofloxacine hydrochloride 10.0 pet 0.272 C-04314. Carbamazepine 1.0 pet 0.042 C-04415. Hydantoin 10.0 pet 0.999 H-02716. Diltiazem hydrochloride 10.0 pet 0.222 D-06017. Captopril 5.0 pet 0.230 C-04518. Acetylsalicylic acid 10.0 pet 0.555 A-03119. Diclofenac sodium salt 1.0 pet 0.031 D-06120. Ketoprofen 1.0 pet 0.039 K-002B21. Piroxicam 1.0 pet 0.030 P-03322. Acetaminophen 10.0 pet 0.661 A-032

23. Acyclovir 10.0 pet 0.444 A-033



50/206


51/206


45

24. Aluminiumchloride hexahydrate 2.0 pet 0.083 A-02225. Camphoroquinone 1.0 pet 0.060 C-02626. N,N-Dimethylaminoethyl methacrylate 0.2 pet 0.013 D-04527. 1,6-Hexanediol diacrylate 0.1 pet 0.004 H-00428. DROMETRIZOLE 1.0 pet 0.044 H-01629. Tetrahydrofurfuryl methacrylate 2.0 pet 0.118 T-02730. Tin 50.0 pet 4.213 T-008

Revised May 1999

Dental Materials Patients DMP-1000

1. Methyl methacrylate 2.0 pet 0.200 M-0132. Triethylene glycol dimethacrylate 2.0 pet 0.070 T-0183. Ethyleneglycol dimethacrylate 2.0 pet 0.101 E-0074. Bisphenol A glycerolate dimethacrylate

(BIS-GMA) 2.0 pet H-0135. 2,2-bis(4-(2-Methacryl-oxyethoxy)phenyl)-

propane (BIS-EMA) 2.0 pet M-006B6. 2-Hydroxyethylmethacrylate 2.0 pet 0.154 H-0107. N,N-Dimethylaminoethyl methacrylate 0.2 pet 0.013 D-0458. Tetrahydrofurfuryl methacrylate 2.0 pet 0.118 T-0279. 1,4-Butanedioldimethacrylate 2.0 pet 0.088 B-017

10. 1,6-Hexanediol diacrylate 0.1 pet 0.004 H-00411. Potassium dichromate* 0.5 pet 0.017 P-014A12. Mercury 0.5 pet 0.025 M-00513. Cobalt(II)chloride hexahydrate 0.5 pet 0.021 C-017B14. Gold(I)sodium thiosulfate dihydrate 2.0 pet 0.040 G-005B15. Nickel(II)sulfate hexahydrate* 5.0 pet 0.190 N-002A16. EUGENOL 2.0 pet 0.122 E-016

17. COLOPHONIUM* 20.0 pet C-02018. N-Ethyl-p-toluenesulfonamide 0.1 pet 0.005 E-01519. Palladium chloride 2.0 pet 0.112 P-00120. CARVONE 5.0 pet 0.333 C-03521. DROMETRIZOLE 1.0 pet 0.044 H-01622. MYROXYLON PEREIRAE RESIN*,** 25.0 pet B-00123. Epoxy resin, Bisphenol A* 1.0 pet E-002

New January 2005





52/206


53/206


54/206


55/206


56/206


57/206


58/206


59/206


53

Metal Series MET-1000

1 Zinc 2.5 pet 0.382 Z-0012 Mercury 0.5 pet 0.025 M-0053 Mercuric chloride 0.1 pet 0.004 M-0044 Aluminiumchloride hexahydrate 2.0 pet 0.083 A-0225 Mercury ammoniumchloride 1.0 pet 0.026 M-022

6 Aluminium 100 A-0217 Palladium chloride 2.0 pet 0.112 P-0018 Gold(I)sodium thiosulfate dihydrate 2.0 pet 0.04 G-005B9 Copper(II)sulfate pentahydrate 2.0 pet 0.125 C-02210 Gold(I)sodium thiosulfate dihydrate 0.5 pet 0.010 G-005A11 Copper(I)oxide 5.0 pet 0.350 C-02112 Tin 50.0 pet 4.213 T-00813 Iridium(III)chloride trihydrate 1.0 pet 0.028 I-01214 Iridium 1.0 pet 0.052 I-01415 Indium 1.0 pet 0.087 I-01516 Titanium nitride 5.0 pet 0.807 T-03917 TITANIUM DIOXIDE 10.0 pet 1.252 T-04018 ZINC CHLORIDE 1.0 pet 0.074 Z-007B19 Titanium(III)oxalate decahydrate 5.0 pet 0.093 T-04120 CALCIUM TITANATE 10.0 pet 0.735 C-049

21 Titanium 10.0 pet 2.088 T-04222 Vanadium 5.0 pet 0.982 V-00223 Molybdenum 5.0 pet 0.521 M-03024 Vanadium(III)chloride 1.0 pet 0.064 V-00325 MANGANESE CHLORIDE 2.0 pet 0.159 M-03126 Stannous oxalate 1.0 pet 0.048 S-01427 Zirconium chloride 1.0 pet 0.043 Z-008

28 Tungsten 5.0 pet 0.272 T-04329 FERRIC CHLORIDE 2.0 pet 0.123 I-01630 PHENYL MERCURIC ACETATE 0.01 aq 0.0003 P-00831 Potassium dicyanoaurate 0.1 aq 0.030 P-01532 SILVER NITRATE 1.0 aq 0.059 S-00733 Cadmium chloride 1.0 aq 0.055 C-00134 Ammonium hexachloroiridate (IV) 0.1 aq 0.002 A-034

35 Indium(III)chloride 10.0 aq 0.452 I-011



60/206

54


36 Lead(II)acetate trihydrate 0.5 aq 0.013 L-00737 Indium sulfate 10.0 aq 0.193 I-01338 Ammonium molybdate (VI) tetrahydrate 1.0 aq 0.008 A-03539 STANNOUS CHLORIDE 1.0 pet 0.053 S-01340 Lead(II)chloride 0.2 aq 0.007 L-00841 Ammonium hexachloroplatinate(IV) 0.1 aq 0.002 A-01042 Ammonium tetrachloroplatinate 0.25 aq 0.007 A-013

New series March 2008

(Meth) Acrylate Series MA-1000 Adhesives, Dental & Other

1. Methyl methacrylate 2.0 pet 0.200 M-0132. n-Butyl methacrylate 2.0 pet 0.141 B-0213. 2-Hydroxyethylmethacrylate 2.0 pet 0.154 H-0104. 2-Hydroxypropylmethacrylate 2.0 pet 0.139 H-0185. Ethyleneglycol dimethacrylate 2.0 pet 0.101 E-0076. Triethylene glycol dimethacrylate 2.0 pet 0.070 T-0187. 1,4-Butanedioldimethacrylate 2.0 pet 0.088 B-0178. Urethane dimethacrylate 2.0 pet 0.041 U-0049. Bisphenol A dimethacrylate (BIS-MA) 2.0 pet M-00710. Bisphenol A glycerolate dimethacrylate

(BIS-GMA) 2.0 pet H-01311. 1,6-Hexanediol diacrylate 0.1 pet 0.004 H-00412. Tetrahydrofurfuryl methacrylate 2.0 pet 0.118 T-02713. Tetraethylene glycol dimethacrylate 2.0 pet 0.061 T-02914. N,N-Dimethylaminoethyl methacrylate 0.2 pet 0.013 D-04515. ETHYL CYANOACRYLATE 10.0 pet 0.799 E-023

Revised May 1999

(Meth) Acrylate Series MN-1000 Nails-Artificial

1. Butyl acrylate 0.1 pet 0.008 B-0182. Ethyl methacrylate 2.0 pet 0.175 E-0123. n-Butyl methacrylate 2.0 pet 0.141 B-021

4. 2-Hydroxyethylmethacrylate 2.0 pet 0.154 H-010



61/206


62/206

56


23. Triethyleneglycol diacrylate 0.1 pet 0.004 T-01724. N,N-Methylene-bisacrylamid 1.0 pet 0.065 M-023 Revised March 2010

Oil & Cooling Fluid Series O-1000

1. ABIETIC ACID 10.0 pet 0.330 A-001

2. p-CHLORO-m-CRESOL (PCMC) 1.0 pet 0.070 C-0083. CHLOROXYLENOL (PCMX) 0.5 pet 0.032 C-010A4. DICHLOROPHENE 1.0 pet 0.038 D-0085. 2-Phenylphenol (o-PHEYNPHENOL) 1.0 pet 0.059 P-0106. PROPYLENE GLYCOL 5.0 pet 0.657 P-019A7. TRIETHANOLAMINE 2.0 pet 0.134 T-0168. 4-tert-Butylbenzoic acid 1.0 pet 0.056 B-0199. 1,2-Benzisothiazolin-3-one 0.05 pet 0.003 B-00310. Hexahydro-1,3,5-tris-(2-hydroxyethyl)triazine 1.0 aq 0.046 H-00211. Bioban P 1487 0.5 pet E-01412. CHLOROACETAMIDE 0.2 pet 0.021 C-00613. N-Methylolchloroacetamide 0.1 pet 0.008 M-01414. BENZOTRIAZOLE 1.0 pet 0.084 B-00615. Ethylenediamine dihydrochloride 1.0 pet 0.075 E-00516. 2-Mercaptobenzothiazole (MBT)* 2.0 pet 0.120 M-003A

17. Zinc ethylenebis-(dithiocarbamate) 1.0 pet 0.036 Z-00518. TRICLOSAN 2.0 pet 0.069 T-01419. 7-ETHYLBICYCLOOXAZOLIDINE 1.0 pet 0.070 A-01720. Bioban CS 1135 1.0 pet D-01521. TRIS(HYDROXY-METHYL)NITRO-

METHANE 1.0 pet 0.066 H-01522. THIMEROSAL (Merthiolate) 0.1 pet 0.003 T-007

23. Hydrazine sulfate 1.0 pet 0.077 H-00524. TRICLOCARBAN (TCC) 1.0 pet 0.032 T-01325. FORMALDEHYDE* 1.0 aq 0.333 F-002A26. Amerchol L 101 50.0 pet A-00427. DIPENTENE (oxidized) 1.0 pet 0.073 D-02028. Sodium-2-pyridinethiol-1-oxide 0.1 aq 0.007 S-00229. 2-BROMO-2-NITROPROPANE-1,3-DIOL 0.25 pet 0.013 B-015A




63/206


57

30. COCAMIDE DEA 0.5 pet C-01931. METHYLISOTHIAZOLINONE +

METHYLCHLORO-ISOTHIAZOLINONE 0.02 aq C-009B

32. 2-Phenoxyethanol 1.0 pet 0.072 P-02533. 2-n-Octyl-4-isothiazolin-3-one 0.1 pet 0.005 O-00434. METHYLDIBROMO GLUTARONITRILE* 0.5 pet 0.019 D-049E

35. IODOPROPYNYL BUTYLCARBAMATE 0.2 pet 0.008 I-008CRevised January 2011

PhotographicChemicals Series P-1000

1. N, N-DIETHYLTOLUENE-2,5-DIAMINE HCL, (CD-2) 1.0 pet 0.047 D-011

2. N-Ethyl-N-(2-methane-sulfonamidoethyl)-2-methyl-1,4-PPD-sesquisulfate, hydrate (CD-3) 1.0 pet 0.023 E-013

3. N-Ethyl-N-(2-hydroxyethyl)-2-methyl-1,4-phenylenediamine sulfate salt (CD-4) 1.0 pet 0.032 E-011

4. p-METHYLAMINOPHENOL SULFATE 1.0 pet 0.029 M-0095. HYDROQUINONE 1.0 pet 0.091 H-0076. 1-Phenyl-3-pyrazolidinone 1.0 pet 0.062 P-004

7. HYDROXYLAMINE HCL 0.1 aq 0.014 H-0118. AMMONIUM PERSULFATE 2.5 pet 0.110 A-0119. Ethylenediamine dihydrochloride 1.0 pet 0.075 E-00510. BENZOTRIAZOLE 1.0 pet 0.084 B-00611. GLUTARAL** 0.2 pet 0.020 G-003A12. BENZYL ALCOHOL 10.0 sof 0.925 B-008B13. HYDROXYLAMINE SULFATE 0.1 aq 0.006 H-01214. Potassium dichromate* 0.5 pet 0.017 P-014A15. N, N-DIETHYL-P-PHENYLENEDIAMINE

SULFATE (TSS) 1.0 pet 0.038 A-00716. Tricresyl phosphate 5.0 pet 0.136 T-015

Revised February 2009





64/206


65/206


59

10. Bisphenol A(4,4-ISOPROPYLIDENEDIPHENOL) 1.0 pet 0.044 B-013

11. Tricresyl phosphate 5.0 pet 0.136 T-01512. Phenol formaldehyde resin (PFR2) 1.0 pet P-00513. p-tert-Butylphenol formaldehyde resin* 1.0 pet B-02414. Triphenyl phosphate 5.0 pet 0.153 T-02215. Toluenesulfonamide formaldehyde resin 10.0 pet T-010

16. Resorcinol monobenzoate 1.0 pet 0.047 R-00217. 2-Phenylindole 2.0 pet 0.104 P-00718. 2-tert-Butyl-4-methoxyphenol (BHA) 2.0 pet 0.111 B-02219. HYDROABIETYL ALCOHOL 10.0 pet 0.344 A-00220. 4-tert-Butylphenol 1.0 pet 0.067 B-02321. 2-Monomethylol phenol 1.0 pet 0.081 M-01522. N,N-Diphenylthiourea (DPTU) 1.0 pet 0.040 D-02523. 2-n-Octyl-4-isothiazolin-3-one 0.1 pet 0.005 O-00424. Cyclohexanone resin 1.0 pet C-02725. Triglycidyl isocyanurate, (TGIC) 0.5 pet 0.016 T-028

Revised January 2001

Rubber Additives Series R-1000

1. Tetramethylthiuram disulfide (TMTD) 1.0 pet 0.042 T-0052. Tetramethylthiuram monosulfide (TMTM) 1.0 pet 0.048 T-0063. Tetraethylthiuram disulfide (TETD) 1.0 pet 0.034 T-0024. Dipentamethylenethiuram disulfide (PTD) 1.0 pet 0.031 D-0195. N-Cyclohexyl-N-phenyl-

4-phenylenediamine 1.0 pet 0.038 C-0246. N,N-Diphenyl-p-phenylenediamine (DPPD) 1.0 pet 0.038 D-0247. N-Isopropyl-N-phenyl-4-phenylenediamine

(IPPD)* 0.1 pet 0.004 I-004

8. 2-Mercaptobenzothiazole (MBT)* 2.0 pet 0.120 M-003A9. N-Cyclohexyl-2-benzothiazyl sulfenamide 1.0 pet 0.038 C-02310. Dibenzothiazyl disulfide (MBTS) 1.0 pet 0.030 D-00311. 2-(4-Morpholinylmercapto)benzothiazol

(MOR) 1.0 pet 0.040 M-01612. 1,3-Diphenylguanidine 1.0 pet 0.047 D-02213. Zinc diethyldithiocarbamate (ZDC) 1.0 pet 0.028 Z-003




66/206


67/206

61


15. 3,3',4',5-Tetrachlorosalicylanilide (TCS) 0.1 pet 0.003 T-00116. Hexachlorophene 1.0 pet 0.025 H-00117. CHLORHEXIDINE DIGLUCONATE 0.5 aq 0.006 C-00518. TRICLOSAN 2.0 pet 0.007 T-01419. Diphenhydramine hydrochloride 1.0 pet 0.034 D-02120. Perfume mix 6.0 pet Mx-08

-CINNAMYL ALCOHOL 1.0 0.075 C-013-CINNAMAL 1.0 0.076 C-014-Hydroxycitronellal 1.0 0.059 H-008-EUGENOL 1.0 0.061 E-016-ISOEUGENOL 1.0 0.061 I-002-GERANIOL 1.0 0.065 G-001

Revised October 1997

Shoe Series SH-1000

1. N-Isopropyl-N-phenyl-4-phenylenediamine(IPPD)* 0.1 pet 0.004 I-004

2. GLUTARAL** 0.2 pet 0.020 G-003A3. DISPERSE ORANGE 3 1.0 pet D-0324. Acid yellow 36 1.0 pet 0.023 A-0195. Hydroquinone monobenzylether 1.0 pet 0.050 H-0196. Thiuram mix* 1.0 pet Mx-01

-Tetramethylthiuram monosulfide (TMTM) 0.25 0.012 T-006-Teramethylthiuram disulfide (TMTD) 0.25 0.010 T-005-Tetraethylthiuram disulfide (TETD) 0.25 0.008 T-002-Dipentamethylenethiuram disulfide (PTD) 0.25 0.008 D-019

7. Potassium dichromate* 0.5 pet 0.017 P-014A8. 4-tert-Butylphenolformaldehyde resin* 1.0 pet B-0249. p-PHENYLENEDIAMINE (PPD)* 1.0 pet 0.028 P-006

10. Nickel(II)sulfate hexahydrate* 5.0 pet 0.190 N-002A11. COLOPHONIUM* 20.0 pet C-02012. FORMALDEHYDE* 1.0 aq 0.333 F-002A13. N,N-Diphenylthiourea (DPTU) 1.0 pet 0.040 D-02514. 2-Mercaptobenzothiazole (MBT)* 2.0 pet 0.120 M-003A15. Diethylthiourea 1.0 pet 0.076 D-039


* Also present in European Baseline Series** Emulsifier: SORBITAN SESQUIOLEATE 5%


68/206

62


16. 1,3-Diphenylguanidine 1.0 pet 0.047 D-02217. N,N-Dibutylthiourea 1.0 pet 0.053 D-03818. Epoxy resin, Bisphenol A* 1.0 pet E-00219. Dodecylmercaptan 0.1 pet 0.005 D-04320. METHYLISOTHIAZOLINONE +

METHYLCHLORO-ISOTHIAZOLINONE 0.02 aq C-009B

21. 4-Aminoazobenzene 0.25 pet 0.013 A-00522. 2-n-Octyl-4-isothiazolin-3-one 0.1 pet 0.005 O-00423. 4,4`-Dithiodimorpholine 1.0 pet 0,042 D-054

Revised March 2008

Sunscreen Series SU-1000

1. BUTYL METHOXYDIBENZOYL-METHANE 10.0 pet 0.320 B-029C2. PABA 10.0 pet 0.730 A-006C3. Homosalate 5.0 pet 0.191 H-0244. 3-(4-Methylbenzyliden)camphor

(4-METHYLBEZYLIDENE CAMPH.) 10.0 pet 0.395 M-024B5. ETHYLHEXYL DIMETHYL PABA 10.0 pet 0.360 E-018D6. BENZOPHENONE-3 10.0 pet 0.435 H-014C7. ETHYLHEXYL METHOXYCINNAMATE 10.0 pet 0.350 E-019C8. BENZOPHENONE-10 10.0 pet 0.415 H-020B9. PHENYLBENZIMIDAZOLE SULFONIC

ACID 10.0 pet 0.365 P-024B10. BENZOPHENONE-4 2.0 pet 0.065 H-023C11. DROMETRIZOLE TRISILOXANE 10.0 pet D-05512. Octocrylene (Uvinul N 539 T) 10.0 pet 0.277 O-009

13. Octyl salicylate 5.0 pet 0.200 O-00714. ETHYLHEXYL TRIAZONE 10.0 pet O-01015. ISOAMYL p-METHOXYCINNAMATE 10.0 pet 0.403 I-00916. Bis-Ethylhexyloxyphenol Methoxyphenyl

Triazine (Tinosorb S) 10.0 pet 0.159 B-03717. Methylene bis-benzotriazolyl

tetramethylbutylphenol 10.0 pet 0.152 M-03218. 2-(4-Diethylamino-2-hydroxybenzoyl)-benzoic




69/206


63

acid hexylester 10.0 pet 0.273 D-06219. DIETHYLHEXYL BUTAMIDOTRIAZONE 10.0 pet 0.131 D-063

20. Disodium phenyl dibenzimidazoletetrasulfonate (Neo Heliopan AP) 10.0 pet 0.148 D-064

Important series to be used in photopatch testing Revised March 2008

Textile Colours & Finish TF-10001. Disperse Yellow 3 1.0 pet D-0362. DISPERSE ORANGE 3 1.0 pet D-0323. Disperse Red 1 1.0 pet D-0344. DISPERSE RED 17 1.0 pet D-0355. Disperse Blue 153 1.0 pet D-0296. DISPERSE BLUE 3 1.0 pet D-026

7. Disperse Blue 35 1.0 pet D-0278. Dimethylol dihydroxy ethylene urea

(Fix. CPN) 4.5 aq 0.253 D-0129. Dimethyl dihydroxy ethylene urea 4.5 aq D-05210. Dimethylol dihydroxy ethylene urea,

modified 5.0 aq D-05011. Disperse Blue 106 1.0 pet D-040

12. Ethyleneurea, melamine formaldehyde mix 5.0 pet 0.116 Mx-16(Fix.Ac)*-Ethyleneurea 4.0 D-012-Melamine formaldehyde 1.0 M-001

13. Urea formaldehyde (Kaurit S) 10.0 pet 0.833 U-00114. Melamine formaldehyde (Kaurit M70) 7.0 pet 0.324 M-00115. Disperse Blue 85 1.0 pet D-02816. Disperse Orange 1 1.0 pet D-03117. Acid Yellow 61 5.0 pet A-02618. Disperse Brown 1 1.0 pet D-03019. Disperse Yellow 9 1.0 pet D-03720. Disperse Blue 124 1.0 pet D-04121. Basic Red 46 1.0 pet B-02622. Reactive Black 5 1.0 pet 0.010 R-004B23. Reactive Blue 21 1.0 pet R-005B


* Emulsifier: SORBITAN SESQUIOLEATE 5%


70/206


71/206


72/206


73/206

67


4. Corticosteroid mix 2.1% pet Mx-23-Budesonide 0.1 B-033

-Tixocortol-21-pivalate 1.0 T-0

Chemo Catalogue 2012

Documents

Transcript of Chemo Catalogue 2012